Torsemide Versus Furosemide in Patients With Acute Heart Failure (from the ASCEND-HF Trial)

Robert J. Mentz, Vic Hasselblad, Adam D. DeVore, Marco Metra, Adriaan A. Voors, Paul W. Armstrong, Justin A. Ezekowitz, W. H.Wilson Tang, Phillip J. Schulte, Kevin J. Anstrom, Adrian F. Hernandez, Eric J. Velazquez, Christopher M. O'Connor

Research output: Contribution to journalArticlepeer-review

31 Scopus citations

Abstract

Furosemide is the most commonly used loop diuretic in patients with heart failure (HF) despite data suggesting potential pharmacologic and antifibrotic benefits with torsemide. We investigated patients with HF in Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure who were discharged on either torsemide or furosemide. Using inverse probability weighting to account for the nonrandom selection of diuretic, we assessed the relation between choice of diuretic at discharge with 30-day mortality or HF hospitalization and 180-day mortality. Of 7,141 patients in the trial, 4,177 patients were included in this analysis, of which 87% (n = 3,620) received furosemide and 13% (n = 557) received torsemide. Torsemide-treated patients had lower ejection fraction and blood pressure and higher creatinine and natriuretic peptide level compared with furosemide. Torsemide was associated with similar outcomes on unadjusted analysis and nominally lower events on adjusted analysis (30-day mortality/HF hospitalization odds ratio 0.89, 95% CI 0.62 to 1.29, p = 0.55 and 180-day mortality hazard ratio 0.86, 95% CI 0.63 to 1.19, p = 0.37). In conclusion, these data are hypothesis-generating and randomized comparative effectiveness trials are needed to investigate the optimal diuretic choice.

Original languageEnglish (US)
Pages (from-to)404-411
Number of pages8
JournalAmerican Journal of Cardiology
Volume117
Issue number3
DOIs
StatePublished - Feb 1 2016

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Torsemide Versus Furosemide in Patients With Acute Heart Failure (from the ASCEND-HF Trial)'. Together they form a unique fingerprint.

Cite this